Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Pediatric Hematology and Oncology|May 9, 2018
Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factorsKleopatra Georgantzi, Erik G Sköldenberg, Mats Stridsberg, et al.
World Journal of Surgery|October 11, 2011
Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral centerOlov Norlén, Peter Stålberg, Kjell Öberg, et al.
Medical Oncology (Northwood, London, England)|September 18, 2007
Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 yearsHenrik Kindmark, Anders Sundin, Dan Granberg, et al.
Journal of Neuroendocrinology|March 13, 2024
Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patientsDimitrios Papantoniou, Katarzyna Fröss-Baron, Ulrike Garske-Román, et al.
Journal of Neuroendocrinology|June 30, 2026
Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracersChristophe M Deroose, Valentina Ambrosini, Johanes Hofland, et al.
European Journal of Endocrinology|July 14, 2004
High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumoursStaffan V Welin, Eva Tiensuu Janson, Anders Sundin, et al.
JAMA Oncology|October 20, 2017
Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With SurvivalKosmas Daskalakis, Andreas Karakatsanis, Ola Hessman, et al.
Neuroendocrinology|October 3, 2019
Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine TumorsGitte Dam, Henning Grønbæk, Halfdan Sorbye, et al.
Journal of Neuroendocrinology|March 16, 2023
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinomaHalfdan Sorbye, Enrique Grande, Marianne Pavel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumorsSara Ekeblad, Anders Sundin, Eva Tiensuu Janson, et al.
Pageof 6